BPC-157 After the July 2026 FDA Vote: Tracking Through the Transition
6 min read
CTO & Co-Founder of miora. Stanford Biodesign, ex-Tesla.
BPC-157 has been one of the most widely-used 503A-compounded peptides for soft-tissue healing, gut repair, and connective-tissue recovery. The July 2026 PCAC vote could change pharmacy access. This is what BPC users should track through the transition, regardless of how the vote goes.
Topics on this page
BPC-157 is on the radar for the July 2026 PCAC vote. The outcome could affect which compounding pharmacies continue dispensing the substance.
Inventory documentation matters. Knowing the exact vial count, concentration, and expiration is the difference between an orderly wind-down and a scramble.
Injection-site rotation matters for BPC specifically because it is often injected at or near the site of injury. The rotation log helps identify which sites are healing and which are not.
BPC-157 is a synthetic peptide derived from a protective sequence in human gastric juice. Compounding pharmacies have dispensed it under 503A for years for indications ranging from acute soft-tissue injury to gut repair to general recovery support. The July 2026 PCAC vote could change which pharmacies can continue compounding it. Whether the vote is favorable, partial, or unfavorable, the protocol users who have structured data going in will navigate the transition better than the ones running on memory. This guide is the BPC-specific tracking detail plus the practical considerations for the transition window.
The community use cases for BPC-157 fall into four buckets, each with a different tracking profile.
Acute soft-tissue injury. Users injecting BPC subcutaneously near a tendon, ligament, or muscle injury. The protocol is usually 4 to 6 weeks. The outcome metric is pain or function in the injured area, daily 1-to-5 scale. Cycle ends when symptoms resolve.
Gut repair. Often oral or sublingual, sometimes injected. Indications range from post-antibiotic recovery to inflammatory bowel symptoms (which are a clinical condition that requires clinician oversight, not self-management). The outcome metric is GI symptom on a daily 1-to-5 scale.
Connective tissue support during heavy training. Long-cycle, often paired with TB-500. The outcome metric is recovery score (often pulled from a wearable like WHOOP) and subjective joint or tendon load tolerance during training.
General recovery and post-surgical support. Short cycle, indication-specific, usually under clinician supervision in a longevity-clinic context.
The tracking dimensions differ across the four. miora's daily check adds an indication-specific dimension based on what the user is running BPC for, so the pain or GI score sits alongside the standard six-dimension rubric.
BPC-157 has tracking specifics that differ from a GLP-1 or a growth-hormone-axis peptide.
Injection-site choice. BPC is often injected at or near the site of indication - subcutaneously near a tendon for soft-tissue injury, near the navel for gut indications, into adipose tissue for general recovery. The site choice is a meaningful part of the protocol and the log should capture it.
Dose flexibility. BPC doses in the community range widely (commonly 250 mcg to 500 mcg per injection, sometimes higher for acute injury). The dose history matters more than for a fixed-titration compound; the log should show what doses produced what outcome trends.
Cycle structure. 4 to 8 weeks on, 2 to 4 weeks off is the common pattern. Some users run continuous; some run pulse cycles. The cycle log determines what comparable data exists for the next cycle.
Frequency. Daily, twice-daily, or every-other-day are all common. The frequency affects vial consumption and timing of outcome measurement.
None of this is exotic, but a generic peptide tracker captures few of these dimensions. miora's BPC log handles all of them in plain text.
The single most important data point on a BPC protocol is the indication-specific outcome score, logged daily on a 1-to-5 scale. The scale anchors matter; here are reasonable defaults by indication.
Soft-tissue pain. 5 = no pain, 4 = mild, 3 = moderate, 2 = significant pain limiting activity, 1 = severe pain. Track the specific structure (e.g., right Achilles, left patellar) and use the same anchor consistently.
Functional capacity in the injured area. 5 = full ROM and load tolerance, 4 = near full, 3 = partial limitation, 2 = significant limitation, 1 = unable to load. Useful alongside pain because pain and function do not always move together.
GI symptom (for gut indications). 5 = no symptoms, 4 = mild infrequent, 3 = moderate, 2 = significant, 1 = severe daily symptoms. Track the specific symptom (bloating, reflux, urgency, etc.).
Sleep quality (for general recovery indications). 5 = excellent, 4 = good, 3 = average, 2 = poor, 1 = very poor. Cross-reference with wearable deep-sleep minutes if available.
Training joint-tolerance (for connective-tissue support). 5 = full load tolerated, 4 = mild, 3 = noticeable, 2 = limiting, 1 = unable to train. Logged on training days only.
The outcome curve is the protocol's report card. Without it, the only data is whether the user feels different, which is a much weaker signal.
If you are running BPC-157 and want to be prepared for any of the PCAC vote outcomes, your inventory should be documented by mid-July. Specifically:
Vial count. How many vials, by concentration.
Reconstitution status. Which vials are reconstituted, when, and with what volume of bacteriostatic water.
Expiration. Both the lyophilized expiration and the reconstituted stability window (typically 30 days for BPC under refrigeration).
Pharmacy source. Which compounder dispensed each vial, with date. This becomes relevant if a specific pharmacy is affected by the vote outcome.
Runway calculation. Based on current dose schedule, how many more weeks of protocol the inventory covers.
miora maintains this automatically as doses are logged. If you have been tracking through the protocol, the inventory summary is already available; if you have been running without a log, the inventory snapshot is the first thing to lock in.
The workflow if BPC access changes after the vote is straightforward in miora.
Day-of-vote summary. If BPC is on the agenda, the July 23 and 24 morning summaries lead with the meeting status and your current inventory and cycle position.
Post-vote response. If the vote restricts BPC compounding, the next morning summary surfaces: your remaining inventory, your current cycle week, the suggested clinician conversation, and the structured outcome data from the protocol to date. The decision to finish the cycle, taper, pause, or transition belongs with you and your prescriber.
Ongoing logging. Through any transition, the daily outcome score continues. If a substitute compound is introduced (which is a clinician decision, not a miora recommendation), the baseline data on BPC outcomes becomes the comparison against which the substitute is measured.
The point is that miora's role is to maintain the structured data and surface the relevant context; the clinical decisions belong outside miora. The compounder-shutdown guide walks the parallel scenario of a pharmacy ceasing operations independent of regulatory change.
A favorable vote - inclusion on the 503A list or deferral with continued access - means the protocol continues. The tracking discipline you established before the vote is still worth maintaining for three reasons.
First, the regulatory direction over multiple meetings has been tightening; the next PCAC meeting will have its own agenda and the structured data position protects you for that one too.
Second, the outcome data accumulated during the pre-vote period is the protocol's actual report card. Whether or not the regulatory environment changes, the daily outcome log is the data that lets you decide intelligently about the next cycle, dose, or stack adjustment.
Third, the clinician relationship benefits from the structured data regardless. A quarterly check-in that opens with 'here is the cycle position, the outcome trend over the protocol, the side-effect log, and the lab panel' is a faster and more productive visit than 'I think it has been going OK.'
BPC-specific thresholds worth bringing to your clinician, vote outcome aside:
Indication outcome score not improving by week three of the cycle. The protocol may not be the right fit for this specific indication.
Injection-site reaction or local swelling that persists more than a week. Site rotation or technique issue worth addressing.
New or worsening systemic symptoms. BPC is generally well-tolerated systemically; a new pattern is worth investigating.
Pain or function score worsening on cycle. The protocol may be inappropriate for the indication or the dose may be wrong.
Sleep disruption or mood drift. Less common with BPC than with growth-hormone-axis peptides but worth tracking. The mood rubric guide applies here too.
Bringing the four-week chart with these flags makes the prescriber conversation specific and faster.
Three boundaries.
This guide is not medical advice and does not recommend BPC-157 for any indication. BPC-157 is not FDA-approved for human use; access in the US has been through compounding pharmacies under 503A. Whether it is appropriate for your situation is a clinician question.
This guide does not predict the July 2026 vote outcome. The PCAC committee deliberates independently and the vote will be what it is. The point of the pre-vote tracking discipline is to be prepared for any outcome with structured data.
This guide does not recommend alternative sources, substitutes, or transitions. If BPC access changes, the substitution decision belongs with your prescriber. miora maintains the data; the clinical conversation lives outside miora. This content is for informational purposes only and is not medical or legal advice. BPC-157 is not an FDA-approved drug. Consult qualified professionals for protocol and regulatory questions.
101
